Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				SDX-105-03 NCT00139841


2.		Bendamustine and Bortezomib Combination Therapy in Indolent NHL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				ZOHT-01/07 26866138LYM1003, NCT00426855


3.		SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				SDX-105-02 NCT00076349

Last Modified: 1/18/2005 First Published: 5/28/2004


4.		Phase II Study of Bendamustine in Patients With Rituximab-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0311059-01 SALMEDIX-SDX-105-01, NCT00085033


5.		Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				jth_002 NCT00204620

Last Modified: 2/13/2008 First Published: 12/22/2005


6.		Phase II Study of Bendamustine and Mitoxantrone Hydrochloride in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				Other, Pharmaceutical / Industry				GCLLSG-CLL2K EU-20551, RIBOSEPHARM-GCLLSK-CLL2K, NCT00274963


7.		Phase II Clinical Study on SyB L-0501 in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				20 to 74				Pharmaceutical / Industry				2007002 NCT00612183


8.		A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Completed				20 to 74				Pharmaceutical / Industry				2006001 NCT00389051

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute